Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 1, 2005, Pages 11-15

  Quan Jr , Walter ^a   Ramirez, Maria ^b   Taylor, Chris ^b   Quan, Francine ^c   Vinogradov, Mikhail ^b   Walker, Paul ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c St Luke's Medical Center of Solon   (United States)

Author keywords

Elderly; Famotidine; Interleukin 2; Kidney cancer; Lymphokine activated killer cell (LAK); Melanoma

Indexed keywords

DOPAMINE; RECOMBINANT INTERLEUKIN 2;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FEVER; DRUG MEGADOSE; ENDOTRACHEAL INTUBATION; EVALUATION; EXERCISE TEST; HEART INDEX; HOSPITAL PATIENT; HUMAN; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INTENSIVE CARE UNIT; KIDNEY CANCER; LIVER DISEASE; LUNG DISEASE; LUNG EDEMA; LYMPHADENOPATHY; MELANOMA; NAUSEA; OXYGEN SUPPLY; PATIENT TRANSPORT; PRIORITY JOURNAL; RIGOR; STEM CELL TRANSPLANTATION; STOMATITIS; SURVIVAL RATE; TREATMENT WITHDRAWAL;

ADENOSINE; AGED; AGED, 80 AND OVER; AGING; CAPILLARY LEAK SYNDROME; FAMOTIDINE; HEMODYNAMIC PROCESSES; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MELANOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 16444374174     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.11     Document Type: Article

References (27)

1. Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histologic types. Cancer Res 1986;46:4973.
2. Weil-Hillman G, Frisch P, Prieve AF, et al. Lymphokine-activated killer activity induced by in vivo interleukin-2 therapy: Predominant role for lymphocytes with increased expression of CD2 and Leu-19 antigens but negative expression of CD16 antigens. Cancer Res, 1989;49:3680.
3. McMannis JD, Fisher RI, Creekmore SP, et al. In vivo effects of recombinant IL-2: I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol 1988;140:1335.
4. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 2000;6(Suppl 1):S11.
5. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907.
6. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
7. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486.
8. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694.
9. Quan WDY Jr, Brick W, Vinogradov M, et al. Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma. Cancer Biother Radiopharm 2004;19:350.
10. Quan WDY Jr, Quan FM. Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2. Cancer Biother Radiopharm 2003;18:535.
11. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993;71:2358.
12. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A National Biotherapy Study Group trial. Cancer 1991;68:1.
13. Gold PJ, Thompson JA, Markowitz DR, et al. Metastatic renal cell carcinoma: Long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J Sci Am 1997;3:S85.
14. Yang JC, Rosenberg SA. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell carcinoma. Cancer J Sci Am 1997;3(Suppl 1):S79.
15. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127.
16. Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989;7:477.
17. Bar MH, Sznol M, Atkins MB, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1990;8:1138.
18. Dutcher JP, Gaynor ER, Boldt DH, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991;9:641.
19. Sondel PM, Kohler PC, Hank JA, et al. Clinical and immunological effects of recombinant Interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561.
20. Sosman JA, Kohler PC, Hank J, et al. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988;80:60.
21. Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988;80:1451.
22. Dillman RO, Wiemann MC, VanderMolen LA, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: A phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm 1997;12:249.
23. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopharm 1997;12:5.
24. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001;24:287.
25. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475.
26. Foon KA, Walther PJ, Bernstein ZP, et al. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. J Immunother 1992;11:184.
27. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275.